NCT05219500进行中（未招募）2 期
PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 115
- 试验地点
- 4
- 主要终点
- To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.
研究概览
简要总结
The treatment regimen will consist of 4 doses of FPI-2265
详细描述
The treatment regimen will consist of 4 doses of FPI-2265, administered at 8 ± 1 week intervals, with an initial activity of 100 kilobecquerel (kBq)/kg (±10%).
Additional doses will be administered at 100 kBq/kg (±10%) with the following exceptions:
- Participants who experience dose-modifying events.
- Participants with a confirmed decline in PSA>=50%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participants aged ≥ 18 years.
- •Participants must have the ability to understand and sign an approved informed consent (ICF).
- •Participants must have the ability to understand and comply with all protocol requirements.
- •Adenocarcinoma of prostate proven by histopathology.
- •Life expectancy of 6 months or more.
- •Unresectable metastases.
- •Documented progressive disease (PD); progressive mCRPC will be based on at least 1 of the following criteria:
- •Serum PSA progression is defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal starting value is 1.0 ng/mL, if PSA is the only indication of progression.
- •Soft-tissue progression defined as an increase ≥ 20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions.
- •Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan (2+2 PCWG3 criteria).
- •If known Breast Cancer gene (BRCA) mutations are present, participants should have received FDA approved therapies such as poly-ADP ribose polymerase (PARP) inhibitors and progressed.
- •Castration resistant disease with confirmed testosterone level ≤ 50 ng/dL under prior androgen deprivation therapy (ADT). Must have a castrate level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L).
- •Positive PSMA PET/CT scans, obtained with approved PSMA-ligands, defined as at least one PSMA-positive metastatic lesion and no PSMA-negative lesions.
- •ECOG-PS 0 to
- •Hemoglobin (Hgb) concentration ≥ 9.0 g/dL.
- •Platelet counts ≥ 100 × 10^9/L.
- •White blood cell (WBC) count ≥ 2.0 × 10^9/L, absolute neutrophil count (ANC) > 1.5 × 10^9/L.
- •a. Hematological criteria cannot be met with ongoing or recent blood transfusions (within 7 days prior to the scheduled first dose of study treatment) or require growth factor support (within 21 days prior to the scheduled first dose of study treatment).
- •Alanine aminotransferase or aspartate aminotransferase ≤ 3.0 × upper limit of normal (ULN).
- •Serum total bilirubin ≤ 1.5 × ULN; in participants with Gilbert's syndrome, a total bilirubin ≤ 3 times ULN and direct bilirubin within normal limits are permitted.
- •Albumin ≥ 2.5 g/dL.
- •Serum/plasma creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min based on the Cockcroft-Gault formula.
- •Prothrombin time, international normalized ratio or prothrombin time test < 1.5 × ULN.
- •Received ≥ 1 androgen receptor axis-targeted therapies (ARAT).
- •Participants on anti-androgen therapy are allowed to continue their treatment at the discretion of their treating physician.
排除标准
- •Less than 6 weeks from enrollment since last myelosuppressive therapy (including Docetaxel, Cabazitaxel, 223Ra, 153Sm, 177Lu-PSMA-617/other Lu-PSMA RLT or any other radionuclide therapy). Participants who received previous treatment with Ac-225 are excluded.
- •Participants who received more than 4 prior lines of systemic therapy for CRPC.
- •Urinary tract obstruction as evidenced by Tc-99m DTPA renal scan with diuretics.
- •Participants with skeletal metastases presenting as a superscan on a 99m Tc MDP Bone Scan.
- •Superscan is defined as a bone scan which demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint renal activity (absent kidney sign).
- •Persistent baseline dry eye or dry mouth > Grade 1 from prior RLT.
- •Persistent prior AEs > Grade 1 from prior anti-cancer therapies.
- •Abnormal renal function (estimated glomerular filtration rate < 60 mL/min), baseline Hgb < 9g/dL, ANC < 1.5 ×10^9/L, platelets < 100 ×10^9/L, and prothrombin time, international normalized ratio or prothrombin time test ≥ 1.5 × ULN.
- •Administration of an investigational agent ≤ 60 days or 5 half-lives, whichever is shorter, prior to Cycle 1, Week
- •Known presence of central nervous system (CNS) metastases or liver metastases.
- •Active malignancy other than low-grade non-muscle-invasive bladder cancer and non-melanoma skin cancer.
- •Concurrent illness that may jeopardize the participant's ability to undergo study procedures as determined by the Investigator.
- •Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
- •Concurrent serious (as determined by the investigator) medical conditions, including, but not limited to, New York Heart Association Class III or IV congestive heart failure, unstable ischemia, uncontrolled symptomatic arrhythmia, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.
- •Major surgery ≤ 30 days prior to enrollment.
- •Planning to conceive pregnancy during the treatment and up to 6 months after the last treatment.
研究组 & 干预措施
FPI-2265
Experimental
All patients will receive FPI-2265, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%).
干预措施: FPI-2265 (Drug)
结局指标
主要结局
To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.
时间窗: From start of treatment until 12 weeks after the first treatment.
Frequency and proportion of participants with PSA50, defined as ≥ 50% decline in PSA level by 12-weeks after the first treatment.
次要结局
- To evaluate the safety and tolerability of FPI- 2265.(From first treatment dose to up to 24 months after last treatment.)
- To assess the impact of FPI-2265 on participant reported outcomes.(From first treatment until 24 months after last treatment.)
- To evaluate the anti-tumor activity of FPI-2265.(From first treatment until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 24 months after last treatment.)
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.Ulcerative ColitisNCT03269695Pfizer20
已完成
2 期
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CHepatitis CNCT00621296Tanabe Pharma Corporation15
已完成
1 期
Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male SubjectsHealthyNCT02070939Pfizer72
已完成
1 期
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaProstate AdenocarcinomaStage IV Prostate CancerStage IVA Prostate CancerStage IVB Prostate CancerNCT03805594University of California, San Francisco43
已完成
2 期
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on MethotrexateRheumatoid Arthritis (RA)NCT03257852Astellas Pharma Inc66